African vaccine maker plans to increase production capacity sevenfold by 2013 Biovac Institute.

Copyright 2009 Advisory Board Company and Kaiser Family Base. All rights reserved.. African vaccine maker plans to increase production capacity sevenfold by 2013 Biovac Institute, a South African vaccine maker, said Mon that it is dealing with other main pharmaceutical firms to improve its annual capacity sevenfold to 35 million dosages by 2013, Reuters reviews. Morena Makhoana, the company’s deputy chief executive, said that 25 million of those doses will stay in Africa. We are in discussions with Sanofi-Pasteur, a unit of Sanofi-Aventis, with GlaxoSmithKline and with Wyeth, who are now called Pfizer, and all three of them have shown a willingness to enter into a technology transfer with one, or a few, of their vaccines currently in the South African market, Makhoana said.Fernandez and her colleagues anticipate that genetic tests of kids with autism shall continue to increase. She and some other experts believe that, based on the analysis results, doctors should encourage these exams for kids who display physical indicators of developmental problems. Doctors could be better able to look after children with autism using these exams, because they will have a basic genetic knowledge of the kid’s condition, Fernandez said. For instance, the genes associated with a child’s autism might predispose them to weight problems or diabetes.